Newsroom
UNITE4TB Annual Meeting 2026: Advancing Innovation and Collaboration in Tuberculosis Research
From April 22–24, 2026, the UNITE4TB Consortium gathered in Munich, Germany, for its Annual Meeting, bringing together partners from across the globe to share progress, exchange insights, and shape the next phase of tuberculosis (TB) research and development.
Hosted by UNITE4TB Partner, Otsuka, at the historical Scholastika event venue in the heart of Munich, the three-day meeting showcased the Consortium’s continued momentum in accelerating the development of improved TB treatment regimens through innovative science, collaboration, and data-driven approaches.
Driving progress across the pipeline
The meeting opened with updates across UNITE4TB’s 12 work packages, highlighting major advances in pharmacology, microbiology, biomarkers, and data science. Presentations demonstrated how integrated approaches — from pharmacometric modeling to AI/ML-driven analyses — are strengthening the Consortium’s ability to optimize treatment strategies and predict outcomes.
Notable progress includes:
- Advances in pharmacological analyses from the DECISION, PARADIGM4TB, and ENABLE studies
- Updates on microbiological methods, including sequencing and ECOFF-based approaches
- Promising biomarker findings, including sputum-based and TB22 signature results
- Continued development of AI/ML tools for treatment outcome analysis
- Strengthened data platforms and responsible data-sharing frameworks
These updates underscored the importance of combining diverse scientific disciplines to address the complexity of TB.
From science to impact: collaboration at the core
Interactive breakout sessions fostered in-depth discussions on key topics, including pharmacometric and pharmacogenomic analyses, antimicrobial stewardship, and strategies to translate UNITE4TB innovations into lasting global impact.
A Joint Advisory Board session explored the challenges and opportunities of including adolescents in future TB clinical trials — highlighting the Consortium’s commitment to more inclusive and representative research.
The meeting also featured exciting updates on UNITE4TB’s clinical trials: DECISION, PARADIGM4TB, and ENABLE, reflecting the breadth and maturity of the UNITE4TB pipeline.
Keynote spotlight: understanding TB heterogeneity
A highlight of the meeting was the keynote address by Dr. Clifton E. Barry III, Chief of the Tuberculosis Research Section at the National Institutes of Health (NIH), titled “Stratifying Tuberculosis: Understanding Disease Heterogeneity to Guide Treatment Duration.”
Dr. Barry emphasized the critical role of understanding disease variability in predicting relapse risk and optimizing treatment duration. His insights reinforced a core theme of the meeting: that precision approaches — grounded in robust data and clinical insight — are essential to transforming TB care.
A panel discussion following the keynote address further explored how these concepts can be translated into clinical trial design and real-world application.
Integrating community perspectives
Recognizing that patient experience is central to successful TB treatment, the meeting agenda included a dedicated session on community perspectives in TB clinical trials. Speakers shared firsthand insights into participant experiences, adherence challenges, and opportunities to improve trial design and implementation.
This session reinforced the importance of embedding patient voices into every stage of the research process.
Strengthening the path from discovery to delivery
Discussions on preclinical and clinical development pathways highlighted how findings from trials such as PARADIGM4TB are informing earlier-stage research and feeding clinical insights back into drug development. These efforts are helping to refine drug development strategies and accelerate progress toward shorter, more effective TB treatments.
The final day of the meeting focused on investigator discussions for both current and future studies, ensuring alignment and coordination across ongoing and upcoming trials.
The 2026 Annual Meeting demonstrated the strength of the UNITE4TB Consortium as a collaborative platform driving innovation in TB research. By integrating cutting-edge science, clinical expertise, and community engagement, the Consortium continues to advance towards its goal of transforming TB treatment.